Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 1;37(4):365-371.
doi: 10.1097/CCO.0000000000001152. Epub 2025 May 5.

Cellular therapies in sarcoma and other solid tumors

Margaux Dupont  1 , Axel de Bernardi, Hélène Vanacker, Armelle Dufresne, Mehdi Brahmi, Jean-Yves Blay
Affiliations
Review

Cellular therapies in sarcoma and other solid tumors

Margaux Dupont et al. Curr Opin Oncol. .

Abstract

Purpose of review: While adoptive cell therapies such as chimeric antigen receptor T (CAR-T) cell have demonstrated efficacy in hematological malignancies, their success in solid tumors remains challenging due to tumor heterogeneity, antigen specificity, and the suppressive tumor microenvironment. This review aims to provide an overview of recent advancements in cellular therapies, in sarcomas and other solid malignancies.

Recent findings: In the field of sarcomas, the approval of afamitresgene autoleucel (afami-cel) for synovial sarcoma in Atoxiciugust 2024 marks a milestone in T cell therapy, demonstrating an objective response rate (ORR) of 39% and a median overall survival (OS) of 16.9 months in the SPEARHEAD-1 phase 2 trial. Other trials exploring NY-ESO-1 specific T-cell receptor-engineered T (TCR-T) therapies in myxoid round-cell liposarcoma (MRCL) have shown promising response rates. Beyond sarcomas, CAR-T therapies targeting CLDN18.2 in gastrointestinal cancers, GD2 in gliomas, and PSCA in prostate cancer have demonstrated varying degrees of efficacy, with ongoing research to date.

Summary: Clinically, these therapies highlight the need for improved patient selection criteria, and optimized antigen targeting. Toxicity management must also be taken into account, as cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) can be severe. Further studies should focus on improving safety and T cell persistence, and refining manufacturing processes to increase accessibility and scalability.

Keywords: CAR-T cell; Cellular therapies; Sarcoma; Solid tumors; TCR-T cell.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Savina M, Le Cesne A, Blay JY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med 2017; 15:78.
    1. Pollack SM, Somaiah N, Araujo DM, et al. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med 2020; 9:4593–4602.
    1. Hong DS, Van Tine BA, Biswas S, et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A∗02+ patients: a phase 1 trial. Nat Med 2023; 29:104–114.
    1. D’Angelo SP, Araujo DM, Razak ARA, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 2024; 403:1460–1471.
    1. Sidaway P. Afami-cel provides a novel treatment option for rare sarcoma subtypes. Nat Rev Clin Oncol 2024; 21:401.

Substances